Preparation of two tanshinone Ⅱ_A-astragaloside Ⅳ co-loaded nano-delivery systems and in vitro antitumor activity comparison / 中国中药杂志

This study screened excellent carriers for co-loading tanshinone Ⅱ_A(TSA) and astragaloside Ⅳ(As) to construct antitumor nano-drug delivery systems for TSA and As. TSA-As microemulsions(TSA-As-MEs) were prepared by water titration. TSA-As metal-organic framework(MOF) nano-delivery system was prepared by loading TSA and As in MOF by the hydrothermal method. Dynamic light scattering(DLS), transmission electron microscopy(TEM), and scanning electron microscopy(SEM) were used to characterize the physicochemical properties of the two preparations. Drug loading was determined by HPLC and the effects of the two preparations on the proliferation of vascular endothelial cells, T lymphocytes, and hepatocellular carcinoma cells were detected by the CCK-8 method. The results showed that the particle size, Zeta potential, and drug loading of TSA-As-MEs were(47.69±0.71) nm,(-14.70±0.49) mV, and(0.22±0.01)%, while those of TSA-As-MOF were(258.3±25.2) nm,(-42.30 ± 1.27) mV, and 15.35%±0.01%. TSA-As-MOF was superior to TSA-As-MEs in drug loading, which could inhibit the proliferation of bEnd.3 cells at a lower concentration and improve the proliferation ability of CTLL-2 cells significantly. Therefore, MOF was preferred as an excellent carrier for TSA and As co-loading.

Advances of immune-vascular crosstalk for oncology therapeutics / 中国药理学通报

Malignant tumor is one of the important reasons threatening human health and safety at present. The application of antiangiogenic drugs and immune checkpoint inhibitors has brought great hope for tumor treatment, but the complex interlaced relationship between tumor blood vessels and immune microenvironment leads to unsatisfactory efficacy. In addition,VEGF, a key driver of tumor angiogenesis, interferes with the maturation of dendritic cells, thereby inhibiting the initiation of T cells. VEGF also induces depletion of CD8+T cells. At the same time, various innate and acquired immune cells secrete angiogenic factors that accelerate uncontrolled angiogenesis and promote vascular immaturity. Therefore targeting tumor blood vessels and immunity is a potential strategy for enhancing tumor immunotherapy. In recent years numerous studies have found that using the blood vessels and the immune intervention strategies combined with antitumor immune therapy has achieved good results. In this review the immune and vascularized tumor microenvironment are reviewed and discussed, and the research progress of vascularized immune interintervention strategy for tumor treatment in recent years is reviewed so as to provide reference for further improving the efficacy of tumor immunotherapy.